Procaps Group SA

As of September 7, 2023, Procaps Group SA is considered a very attractive investment due to its undervaluation indicated by a P/E ratio of 5, a Price to Book Value of 0.59, and a PEG ratio of 0.05, despite a 44.76% decline in stock performance over the past year.

As of June 20, 2025, the trend is mildly bearish due to daily moving averages and weekly RSI indicating bearish momentum, despite some mildly bullish signals from MACD and KST, with overall caution advised due to underperformance against the S&P 500.

Procaps Group SA is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $118 million and a net profit of $8 million as of September 2023. It has a market cap of $2.58 billion and key metrics include a P/E ratio of 5.00 and a debt-to-equity ratio of 6.92.

As of Jun 18, Procaps Group SA has a market capitalization of 2,580.59 million, with net sales of 414.10 million and a net profit of 52.20 million over the latest four quarters. The balance sheet as of Dec 22 shows shareholder's funds of -0.94 million and total assets of 460.19 million.